Francesco Donato

Prof. Francesco Donato

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2004 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
GFGiovanna Fattovich
Giovanna Fattovich
TSTommaso Stroffolini
Tommaso Stroffolini
IZIrene Zagni
Irene Zagni
FDFrancesco Donato
Francesco Donato

1 October 2008 in Journal of Hepatology
Verified
Journal Article
Closed access
GRGiovanni Raimondo
Giovanni Raimondo
JAJean-Pierre Allain
Jean-Pierre Allain
Maurizia Rossana BrunettoMaurizia Rossana Brunetto
Maurizia Rossana Brunetto
MBMarie-Annick Buendia
Marie-Annick Buendia
DCDing-Shinn Chen
Ding-Shinn Chen
Fabien ZoulimFabien Zoulim
Fabien Zoulim

15 February 2002 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
FDFrancesco Donato
Francesco Donato
ATA. Tagger
A. Tagger
UGU. Gelatti
U. Gelatti
GPG. Parrinello
G. Parrinello
PBP. Boffetta
P. Boffetta
GNG. Nardi
G. Nardi
The authors investigated the dose-effect relation between alcohol drinking and hepatocellular carcinoma (HCC) in men and women separately, also considering hepatitis B and hepatitis C virus infections. They enrolled 464 subjects (380 men) with a first diagnosis of HCC as cases and 824 subjects (686 men) unaffected by hepatic diseases as controls; all were hospitalized in Brescia, northern Italy, in 1995–2000. Spline regression models showed a steady linear increase in the odds ratio of HCC for increasing alcohol intake, for values of >60 g of ethanol per day, with no substantial differences between men and women. Duration of drinking and age at start had no effect on the odds ratio when alcohol intake was considered. Former drinkers who had stopped 1–10 years previously had a higher risk of HCC than current drinkers did. The effect of alcohol drinking was evident even in the absence of hepatitis B or hepatitis C virus infection. In addition, a synergism between alcohol drinking and either infection was found, with approximately a twofold increase in the odds ratio for each hepatitis virus infection for drinkers of >60 g per day.

30 January 1998 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
FDFrancesco Donato
Francesco Donato
PBPaolo Boffetta
Paolo Boffetta
Massimo PuotiMassimo Puoti
Massimo Puoti
The aim of the study was to assess whether co‐infection by hepatitis‐B virus (HBV) and hepatitis‐C virus (HCV) is associated with a higher risk of developing hepatocellular carcinoma (HCC) than each infection alone. A meta‐analysis of data published up to June 1997 was performed. HBsAg and anti‐HCV antibodies or HCV RNA (anti‐HCV/HCV RNA) were considered as serological markers of current HBV and HCV infection respectively. A total of 32 case‐control studies were suitable for a quantitative overview. The summary odds ratios (OR) were 13.7 for HBsAg positivity and 11.5 for anti‐HCV/HCV RNA positivity. The OR for anti‐HCV was lower among studies using second‐ or third‐generation anti‐HCV or HCV RNA (OR, 8.2) with respect to studies with first‐generation anti‐HCV test (OR, 19.1). When combining data from the studies with second‐ or third‐generation anti‐HCV or HCV RNA, the OR for HBsAg positivity and anti‐HCV/HCV RNA negativity was 22.5 (95% confidence interval (CI), 19.5–26.0), the OR for anti‐HCV/HCV RNA positivity and HBsAg negativity was 17.3 (95% CI, 13.9–21.6), and the OR for both markers positivity was 165 (95% CI: 81.2–374, based on 191 cases and 8 controls exposed). A synergism was found between HBV and HCV infections, the OR for co‐infection being greater than the sum and lower than the product of those for each infection alone. The interaction was therefore negative according to the multiplicative model, providing epidemiological evidence both of an independent effect and of interference between the 2 viruses in the carcinogenic process. Int. J. Cancer 75:347–354, 1998.

1 July 2007 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
GCGino Roberto Corazza
Gino Roberto Corazza
VVVincenzo Villanacci
Vincenzo Villanacci
CZClaudia Zambelli
Claudia Zambelli
Massimo MilioneMassimo Milione
Massimo Milione
OLOmbretta Luinetti
Ombretta Luinetti
FDFrancesco Donato
Francesco Donato

28 March 2000 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
PBPaul Brennan
Paul Brennan
OBOlivier Bogillot
Olivier Bogillot
SCSylvaine Cordier
Sylvaine Cordier
EGEberhard Greiser
Eberhard Greiser
WSWalter Schill
Walter Schill
PBPaolo Boffetta
Paolo Boffetta
The primary risk factor for bladder cancer is cigarette smoking. Using a combined analysis of 11 case‐control studies, we have accurately measured the relationship between cigarette smoking and bladder cancer in men. Available smoking information on 2,600 male bladder cancer cases and 5,524 male controls included duration of smoking habit, number of cigarettes smoked per day and time since cessation of smoking habit for ex‐smokers. There was a linear increasing risk of bladder cancer with increasing duration of smoking, ranging from an odds ratio (OR) of 1.96 after 20 years of smoking (95% confidence interval [CI] 1.48–2.61) to 5.57 after 60 years (CI 4.18–7.44). A dose relationship was observed between number of cigarettes smoked per day and bladder cancer up to a threshold limit of 15–20 cigarettes per day, OR = 4.50 (CI 3.81–5.33), after which no increased risk was observed. An immediate decrease in risk of bladder cancer was observed for those who gave up smoking. This decrease was over 30% after 1–4 years, OR = 0.65 (0.53–0.79), and was over 60% after 25 years of cessation, OR = 0.37 (0.30–0.45). However, even after 25 years, the decrease in risk did not reach the level of the never‐smokers, OR = 0.20. (0.17–0.24). The proportion of bladder cancer cases attributable to ever‐smoking was 0.66 (0.61–0.70) for all men and 0.73 (0.66–0.79) for men younger than 60. These estimates are higher than previously calculated. Int. J. Cancer 86:289–294, 2000.